abn ambro morgan

7th September, 2007.

Ventracor (VCR) - Buy. Price Target: $1.17, Share Price: 63c;
Market Cap: $188m.
VCR announced the enrolment of the first patient in the US
Destination Therapy (DT) trial. The DT trial is the
second trial being undertaken in the US - the other trial is a Bridge to
Transplant trial which commenced in June 2007.
The DT trial is designed as two modules. The first module will be
randomised to the existing treatment arm and involve about 180 patients.
The second module will be randomised against an existing FDA
approved LVAD and involve 45 patients. It is expected the enrolment for
the DT trial will take about two years.
The announcement is another milestone ticked off for the
company.